Healthcare and Biotech Inflection via AI and Capital Rotation

Conviction: 75% · Horizon: 5Y · 2026-07-16
Capital can rotate from a $13.5T semiconductor complex into a $1.5T biotech complex, while AI reframes healthcare as a computational growth trade.

Investable biotech is small versus semis, so even modest rotation can move prices. Multi-year advances in mortality, metabolic disease, plaque reversal, GLP-1 longevity framing, and AI across diagnosis-to-treatment create a self-reinforcing healthcare value cycle still early in market recognition.

Instrument Side Target Reason
ABCL Long An AI-driven antibody discovery platform can compress candidate finding to weeks, monetize via partner royalties across a broad pipeline, and add asymmetric upside from owned assets; a large cash buffer versus market cap cushions binary trial risk and leaves equity as a leveraged call on successful proprietary data and partner progress.
TEM Long A multi-year lead in multimodal patient and clinical data creates a compounding flywheel from sequencing and diagnostics into pharma licensing; at a mid-single-digit sales multiple the market still prices a diagnostics lab more than a scarce data-and-applications platform, leaving room for re-rating if diagnostics growth and higher-margin data revenue both compound.
LLY Long Scale in commercialization plus exposure across AI-enabled discovery and data infrastructure positions a leading GLP-1 franchise at the intersection of longevity therapeutics and the broader shift of healthcare into a computational AI trade, capturing both product economics and ecosystem optionality.

Themes

The content on this page is for informational purposes only and does not constitute financial advice. Stoquate is not a licensed financial advisor. Always conduct your own research and consult a qualified professional before making any investment decisions.